ASH Update - Brochure

Best
of
ASH-2016
&
st
21 Annual CME in Hematology
With International faculty
Thurs-Sat, 19th - 21st Jan, 2017

Hotel ITC Grand Central, Parel, Mumbai, India
Mumbai Hematology Group
With compliments from
Executive Committee
President
Dr. M.B. Agarwal
Vice-President
Dr. Farah Jijina
Secretary
Dr Swati Kanakia
Treasurer
Dr. Brijesh Arora
Members
Dr Shubhangi Agale
Dr. S.D. Banavali
Dr. Roshan Colah
Dr. Mukesh Desai
Dr. S. Khodaiji
Dr. Vrinda Kulkarni
Dr. Mamta Manglani
Dr. Navin Khattry
Dr Chandrakala S
Dr. Asha Shah
Dr Shrimati Shetty
Best
of ASH-2016 &
st
21 Annual CME in Hematology
Dear Colleague,
Best of ASH-2016 (which will be held in San Diego in December 2016) and 21st Annual CME in
Hematology will be held under the aegis of Mumbai Hematology Group (MHG) at Hotel ITC
Grand Central, Parel, Mumbai from Thursday to Saturday, 19th to 21st January 2017.
We have already engaged some of the top international faculty from US and Europe for this
event. Emphasis will be on the newer data that will be presented during ASH-2016. We will be
discussing both basics as well as applied aspects (Diagnostic and Therapeutic). Pediatric
subjects will also be covered.
As usual, Team from Nucleus (Mr. Rajesh Sharma, Mr. Yash Agarwal, Mr. Kalpesh Pambhar and
others) has been appointed for managing the event.
The meeting will begin with lunch on day 1 and end with lunch on day 3. You can arrive in the
morning of day 1 and leave by late afternoon on day 3. A large number of rooms have been
booked at same hotel for 2 nights i.e. Thursday and Friday (19th & 20th of January 2017).
Early registration for this event will be the key to make it an economical affair.
Looking forward to your kind participation which will make this academic feast a grand event.
Your sincerely
Dr M B Agarwal, MD
Hematologist & Hemato-Oncologist
President - Mumbai Hematology Group
Best of ASH-2016 & 21st Annual CME in Hematology

International faculty
Dr. Flora Peyvandi, MD, PhD

Professor of Internal Medicine
Director of the Angelo Bianchi Bonomi Haemophilia
and Thrombosis Centre
Fondazione IRCCS Ca Granda
Ospedale Maggiore Policlinico
Milan, Italy
Dr. Sabine Eichinger

Professor of Medicine
Department of Internal medicine
Medical University of Vienna
Karl Landsteiner Institute of Thrombosis Research,
Vienna, Austria
Dr Henrik Hasle
Professor
Department of Paediatrics,
Aarhus University Hospital Skejby,
Aarhus, Denmark
Dr Ajay Nooka
Assistant Professor
Division of Bone Marrow Transplant
Department of Hematology and Medical Oncology,
Winship Cancer Institute of Emory University,
Atlanta, Georgia, USA

Dr. Naval Daver

Assistant Professor
Leukemia Department
MD Anderson Cancer Center
Houston, Tx, USA
Dr. Ghulam Mufti

Director of King's College Hospital NHS Foundation Trust
Professor of Haemato-oncology,
Clinical Director of Pathology
Head of the Department of Haematology
King's College Hospital, London, UK
John Mascarenhas, MD
Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, USA
Dr Nathan Fowler
Associate Professor,
Department of Lymphoma
The University of Texas MD Anderson
Cancer Center, Houston, TX, USA

Dr A C Newland
Professor
Department of Haematology
Barts Health NHS trust - The Royal London Hospital
London, UK
Dr Neal Young, MD
Senior Investigator
Cell Biology Section, Hematology Branch
National Heart, Lung and Blood Institute
National Institutes of Health, Bethesda, MD, USA
Dr Genoveffa Franchini, MD
Center for Cancer Research
National Cancer Institute (NCI)
National Institutes of Health
Bethesda, MD, USA
Dr Mala K Talekar, MD
Attending Physician, Cancer Immunotherapy Frontier Program
Division of Oncology & Blood and Marrow Transplantation
Department of Pediatrics
The Childrens Hospital of Philadelphia,
Philadelphia, USA

Who will speak on what !
Dr Ajay K Nooka
1. Definition and management of high risk myeloma: progress in the last decade
2. Newer Therapeutic options for R/R myeloma: focus on Carfilzomib
3. ASH 2016 updates in myeloma
Dr Ghulam Mufti
1. Low risk MDS - What is new ?

2. High risk MDS - What is new ?
3. Pathobiology of MDS - What is new ?
Dr Naval Daver
1. A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017

2. AML: Highlights of Molecular and Immune Therapies from ASH 2016
3. The future of Hypomethylating Agents in AML: Building Optimal Combinations
Dr John Mascarenhas 1. Ruxolitinib the past, present and what to expect in the future
2. Case based clinical approach to modern management of ET, PV and PMF, as
well as MPN related AML
3. Updates on MPN from ASH 2016
Dr Hasle Henrik
1. Myelodysplastic and Myeloproliferative Disorders of Childhood

2. Management of childhood AML
3. Late complications in survivors of AML
Dr Mala Talekar
1. Chimeric Antigen Receptor (CAR) Modified T cell Therapy for relapsed /

refractory pediatric leukaemias
Dr Neal Young
1. Immunology of acquired aplastic anemia: pathophysiology and treatment

2. Telomere disease and other constitutional marrow failure syndromes in adults
3. Eltrombopag as stem cell stimulation in bone marrow failure
Dr A C Newland
1. How do I treat ITP in 2017 ?

2. A to Z about Romiplostim in the treatment of ITP
3. Platelets : What was new in ASH-2016 ?
Dr Flora Peyvandi
1. Thrombotic thrombocytopenic purpura - Advances

2. Hemophilia : Diagnosis, treatment and complications - The past and future
3. Bleeding disorders - Advances in treatment
Dr Sabine Eichinger
1. All about DOACs

2. Recurrent DVT - All that a clinician should know
3. Cancer related thrombosis
Dr Gnoveffa Fanchini
Dr Andy Fowler
1. From animal studies to men and back: Prospective in the development of a

vaccine for HIV
To be decided

Know your faculty
1. Dr Adrian C Newland
l
Dr Adrian
Newland is Professor of Haematology at Barts Health NHS Trust,

London, UK and at Queen Mary University of London.
l
His
clinical interests are in immune haematology and he jointly developed

the National Registry for Immune Thrombocytopenia to collect
comprehensive epidemiological and clinical data.
l
His
group is undertaking research into the molecular and immune basis of

autoimmune disease and he has an active clinical research programme in
novel treatments.
l
He helped
develop the ITP Clinical Network in the UK and he has developed

guidelines and clinical studies in ITP.
l
He is
Chair of the National Institute for Health and Care Excellence (NICE)
Diagnostic Assessment Programme.
l
He is
ex-President of the British Society for Haematology, was President of

the Royal College of Pathologists from 20052008, and President of the
International Society of Hematology (ISH) from 2016 - 2016.
l
He
is Senior Editor of Hematology, the journal of the ISH, and he has

published over 300 peer-reviewed papers in international journals including
Blood, the British Journal of Haematology, The Lancet and the American
Journal of Hematology.
l
He is current advisor to NHS England on pathology
2. Dr Henrik Hasle
l
He
is professor in pediatric hematology/oncology at the department of

Pediatrics, Aarhus University Hospital Skejby in Aarhus, Denmark.
l
He
received his doctor of medicine degree from Odense University,

Denmark.
l
He trained in epidemiology, hematology and pediatrics at Odense University
Hospital, where he also completed a research fellowship in pediatric

oncology with a thesis on myelodysplastic syndrome.
l
Since
2000, he was consultant and associate professor in pediatric

hematology/oncology at Aarhus University Hospital Skejby in Aarhus
Denmark and was subsequently awarded full professor in 2009.
l
He
is a founding member of the European Working group on

Myelodysplastic Syndromes in Childhood (EWOG-MDS) and served as
chairman of the group 1998-2002.
l
He was
the chairman of the AML group of the Nordic Society for Pediatric
Hematology and Oncology (NOPHO) 2002 to 2010 and continues as
responsible for the data managing of the NOPHO-AML protocols.
l
He is the chairman of the International-BFM-AML group from 2016.
l
He is
the author or coauthor of more than 210 peer reviewed journal articles
mainly dealing with myeloid leukemia in children, genetic predisposition to
cancer, and late effects after cancer therapy.

Know your faculty
3. Dr John Mascarenhas
l
He is
an Associate Professor of Medicine at the Icahn School of Medicine at

Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York
City.
l
As a
clinical investigator in malignant hematology with a focus in translational

research involving Myeloproliferative Neoplasms (MPNs), he is primarily
responsible for the clinical trials portion of the Myeloproliferative Disorders
Program at ISMMS.
l
He is
also the Principal Investigator (PI) of the clinical trials project within the
National Cancer Institute sponsored Myeloproliferative Disorder Research
Consortium (MPD-RC).
l
He has
served as PI or Study Chair of multiple investigator-initiated and

industry-sponsored early and late phase clinical trials evaluating innovative
approaches to the treatment of MPNs.
4. Dr Naval Daver
l
He is
an Assistant Professor in the Department of Leukemia at MD Anderson

Cancer Center in Houston, Texas.
l
He completed his medical school from Grant Medical College and Sir J J group
of hospitals, Mumbai followed by a residency and fellowship in hematologyoncology from Baylor College of Medicine.
l
He has
published more than 100 peer reviewed manuscripts focusing on

emerging therapies and clinical trials in AML and myelofibrosis.
l
He is PI or Co-PI for over 25 ongoing multicenter or investigator initiated clinical
trials with a focus in development of immune (Checkpoints, Vaccines,

Monoclonals) and Molecular Therapies in AML and Myelofibrosis.
l
He is
a member of the MDACC Hematology-Oncology Fellowship Steering

committee and Course Director for the Leukemia Department.
l
He is
a PI, Co-PI or collaborator on extramural grants including Leukemia

Lymphoma Society Therapy Acceleration Program, Ladies Leukemia League,
MDACC Leukemia SPORE, and MDACC CPRIT grant.

Know your faculty
5. Dr Mala K Talekar
l
She
completed her medical school training from Grant Medical College & Sir
JJ Group of Hospitals, Mumbai, India, with honors in 2001.
l
She
then did a residency in Pediatrics from Sir HN Hospital & Research

Center, Mumbai, India with DCH and DNB certifications.
l
Her passion
to obtain advanced training in Pediatric Hematology Oncology

led her to United States and after finishing a Pediatric residency from
Children's Hospital of Philadelphia (CHOP) in 2011.
l
She completed fellowship training in Pediatric Hematology Oncology & Bone
Marrow Transplant at Penn State Hershey Children's Hospital in 2014.

l
During
her fellowship, the death of a teenaged patient due to a rare form of

lymphoma despite multiple forms of treatment led her to pursue bench
research evaluating TRAIL-based agents in hematologic malignancies.
l
She
found that a newly discovered small molecule TIC10 (now ONC201)

could induce apoptotic death in a broad panel of lymphoma cell lines.
l
Her
early success helped her obtain prestigious research grants like

American Society of Clinical Oncology (ASCO)'s Conquer Cancer
Foundation's Young Investigator Award and Live Like Bella Childhood Cancer
Foundation's Research funding to support her ongoing research for further
drug development of this exciting molecule.
l
She
then joined the Children's Hospital of Philadelphia's Cancer

Immunotherapy Frontier Program as an Attending Physician where she is an
investigator on clinical trials evaluating Chimeric Antigen Receptor (CAR)
Modified T Cell therapy in relapsed/ refractory pediatric leukemias/
lymphomas.
l
Due
to their unprecedented success, CAR-T based immunotherapies have

been designated as a Novel Breakthrough Therapy for pediatric ALL and are
on their way to potentially becoming the next standard of care for pediatric
ALL.
l
In a research
role, she also actively pursues translational research in further

developing the drug ONC201 for several pediatric cancers with a goal to
bringing it to a clinical trial in pediatric malignancies.

Know your faculty
6. Dr Genoveffa Franchini
l
She
is a renowned Retrovirologist who has pioneered research on

oncogenes and human retroviruses (HTLVs and HIVs) at the Center of
Cancer Research at the National Institute of Health, Bethesda, MD, USA.
l
As a Chief
of the Animal Models and Retroviral Vaccines Section, her lab has
been working on HTLV-1 that causes leukemia and a progressive spastic
myelopathy as well as in HIV pathogenesis and vaccine development using
non-human primate models.
l
One of
the vaccines developed and tested in Dr. Franchini's laboratory is in

clinical trials in 16,000 volunteers in Thailand. Dr. Franchini's laboratory
genetically characterized SIV (Nature 1987) and defined the regulatory
function of HIV-1/2 and SIV genes (Science 1986, 1990).
l
Dr. Franchini
serves the scientific field through editorial duties and has been
an Associate Editor for Blood, Mucosal Immunology, and AIDS Reviews, and
is in frequent demand to review manuscripts for journals including: Journal
of Clinical Investigation, Journal of Experimental Medicine, Journal of
Immunology, Journal of Infectious Diseases, Journal of Virology, Nature
Medicine, Nature Reviews Immunology, Science and Oncogene.
l
She serves
on scientific committees, faculties, and advisory and review

boards in intramural and extramural capacities.
l
Dr. Franchini's
major research interests are: (1) to investigate how HTLV-1

proteins subvert cellular and physiological pathways of T cells and lead to
their transformation and (2) to develop strategies for preventive vaccines and
therapeutic vaccines for HIV-1.

Know your faculty
7. Dr. Flora Peyvandi
l
She is
Professor of Internal Medicine at the University of Milan and the

Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre,
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
l
She received her medical degree from the University of Milan, Italy, is certified
in Haematology and was awarded PhDs from the Maastricht University, The
Netherlands and the University of Milan, Italy for her research in the field of
rare bleeding disorders.
l
Her basic
and medical science research has focused on the investigation of

coagulation disorders.
l
Her research
in the prevalence and mechanism of coagulation disorders

aims at developing cost-effective treatment for the widespread treatment of
patients.
l
She has authored and co-authored more than 310 scientific publications that
have been published across well-known specialized journals (IF of about

1600, H index WoS of 43) and also 18 chapters in various books.
l
Since
1999, she has been invited as an expert speaker at more than 100
national and international meetings and congresses.
l
She has
been the successful recipient of more than 40 project grants funded

by Italian and International organizations and she was the principal
investigator of the Establishment of an European Network of Rare Bleeding
Disorders programme.
l
She participates
in clinical, educational and research activities in different

parts of the world and she was Chair of the International Society of
Thrombosis and Haemostasis (ISTH) Scientific and Standardization
Committee on Factor VIII, Factor IX and Rare Coagulation Disorders.
l
She is
member of the ISTH council, member of the Executive Committee of

the World Federation of Hemophilia (WFH), member of the executive
committee of the European Association for Haemophilia and Allied Disorders
(EAHAD) and member of the Medical Advisory Group of the European
Hemophilia Consortium (EHC).
l
In 2014
she was awarded the Great Hippocrates " that is delivered to Italian
medical researcher of the year.

Know your faculty
8. Dr. Sabine Eichinger
l
She received
her medical and scientific training at the Dept. of Medicine I at

the Medical University of Vienna, and at the Beth Israel Hospital, Harvard
Medical School, in Boston, USA.
l
She is associate professor of medicine and head of the anticoagulation clinic
at the Medical University Hospital of Vienna, Austria.

l
She has broad clinical and scientific experience in the field of thrombosis and
haemostasis and is an expert in designing and conducting clinical studies.

l
She
has vast experience in investigating mechanism of action of

procoagulants and anticoagulants and in evaluating the role of risk factors
and biomarkers for thrombotic disease.
l
She serves
as the principal investigator of several interventional studies on

anticoagulation in patients with venous thromboembolism or atrial fibrillation.
l
She is
past-chairman of the Scientific and Standardization Subcommittee of

the International Society on Thrombosis and Haemostasis (ISTH) and served
as a Council Member of the Society.
l
She is a recipient of several international and national academic awards.
9. Dr Neal Young
l
Dr Young
is the Chief of the Hematology Branch of the National Heart, Lung,

and Blood Institute.
l
He graduated from Harvard College and Johns Hopkins School of Medicine
l
He did medical residency at the Massachusetts General Hospital and training
in hematology at Washington University in St. Louis.

l
Post-doctoral
fellowships in biochemistry and molecular biology were at the

National Institutes of Health, with Drs. Alan Schecter and Arthur Nienhuis.
l
His research
interests are bone marrow failure, normal and abnormal

hematopoiesis, viral infections of marrow cells, autoimmunity, and
mechanisms of genomic instability and leukemogenesis.
l
His work
includes clinical trials in his bone marrow failure clinic in Bethesda

(immunosuppression, telomere modulation, stem cell stimulation), basic
science in virology, immunology, and cell biology (parvovirus B19,
telomerase gene mutations, immune pathogenesis of marrow failure), and
epidemiology ( the largest population based study of aplastic anemia, in
Thailand.
l
He has
published almost 400 original research articles, more than 150

reviews and chapters, and 10 monographs.
l
His laboratory has trained dozens of world leaders in hematology.
Abstracts are invited for poster presentation

l
during Best of ASH-2016
Please note that these will be e-Posters
l
Following are the guidelines for the same
l
An e-Poster is an electronic version of a poster presentation.

l
The e-Poster presentations must be prepared in PowerPoint.
l
As an e-Poster presenter you are asked to prepare a PowerPoint
l
presentation up to a maximum of 08 slides.
It may include text, figures, charts, tables, images, and artwork but an
l
e-Poster digital presentation does not include any audio, video or animation.
Do not use special fonts which are not part of the standard PowerPoint
l
package as this will cause problems while uploading your file.
Set the slide size of the page to On-screen show and landscape
l
orientation in the page set-up section.
Portrait orientation will not be displayed properly.
l
Three best abstracts will be invited to do oral presentation.
l
Recommended Format:
Slide 1
Title + Authors
Slide 2
Introduction
Slide 5 - 7
Results
Slide 3
Objectives
Slide 4
Materials & Methods
Slide 8
Conclusions
Registration fee
Category
Up to 31st December 2016
Spot Registration
Fellow / Trainee / Resident
` 9000 /-
` 21000 /-
All other delegates
` 11000 /-
` 21000 /-
All registrations after 31st December 2016 will be considered as spot registrations
Note:
l
Registration
is mandatory for all participants.
l
Registrations
l
Registration
will be restricted to first 150 delegates
fee includes lunch on all 3 days.
Accommodation
Accommodation is available at Hotel ITC Grand Central, Parel, Mumbai which is the venue of the meeting.
It will be available only for 2 nights i.e. from 12 noon on Thursday, 19th January 2017 to 12 noon on Saturday,
21st January 2017.
There are 2 options :
a) Single room, single occupancy : ` 13,000/- per night.
b) Double room, double occupancy : ` 15,000/- per night.
Note: For double room - double occupancy, delegates have to forward 2 names themselves.
All payments are to be made in favour of : Mumbai Hematology Group
Refund policy
Refunds towards registration will be done only until 15th December 2016 after deducting 50% towards
administrative charges. Refunds towards accommodation will be done after deducting one day hotel stay
charges. The refunds will be done only on receipt of email indicating the same and one month after the
conference is over.
Online registration
For online registration, you can go to the following link
http://in.eregnow.com/ticketing/register/ASH2016ANNUALCME
Address for all correspondence :
Dr M B Agarwal, Course coordinator,

Best of ASH-2016
Hematology Clinic, Ghamat Lodge, 804-A,
Dr B Ambedkar Road, Dadar TT, Mumbai 400014, India.
Cell
: +91 9820024850,
Email ID : mbagarwal1@hotmail.com
mhgpho@hotmail.com
Website : www.bestofash2016.com
Event Manager :
Nucleus
Mr. Rajesh Sharma
Mr. Yash Agarwal
Mr. Kalpesh Pambhar
: + 91 9374073512
: + 91 8790612727
: + 91 9601608846

ASH Update - Brochure

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ASH Update - Brochure

Uploaded by

Copyright:

Available Formats

Best

Thurs-Sat, 19th - 21st Jan, 2017

Mumbai Hematology Group

With compliments from

Best of ASH-2016 & 21st Annual CME in Hematology

Dr. Flora Peyvandi, MD, PhD

Dr. Sabine Eichinger

Best of ASH-2016 & 21st Annual CME in Hematology

Dr. Naval Daver

Dr. Ghulam Mufti

Best of ASH-2016 & 21st Annual CME in Hematology

Best of ASH-2016 & 21st Annual CME in Hematology

1. Low risk MDS - What is new ?

1. A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017

1. Myelodysplastic and Myeloproliferative Disorders of Childhood

1. Chimeric Antigen Receptor (CAR) Modified T cell Therapy for relapsed /

1. Immunology of acquired aplastic anemia: pathophysiology and treatment

1. How do I treat ITP in 2017 ?

1. Thrombotic thrombocytopenic purpura - Advances

1. All about DOACs

1. From animal studies to men and back: Prospective in the development of a

Best of ASH-2016 & 21st Annual CME in Hematology

Newland is Professor of Haematology at Barts Health NHS Trust,

clinical interests are in immune haematology and he jointly developed

group is undertaking research into the molecular and immune basis of

develop the ITP Clinical Network in the UK and he has developed

ex-President of the British Society for Haematology, was President of

is Senior Editor of Hematology, the journal of the ISH, and he has

is professor in pediatric hematology/oncology at the department of

received his doctor of medicine degree from Odense University,

Hospital, where he also completed a research fellowship in pediatric

2000, he was consultant and associate professor in pediatric

is a founding member of the European Working group on

Best of ASH-2016 & 21st Annual CME in Hematology

an Associate Professor of Medicine at the Icahn School of Medicine at

clinical investigator in malignant hematology with a focus in translational

served as PI or Study Chair of multiple investigator-initiated and

an Assistant Professor in the Department of Leukemia at MD Anderson

published more than 100 peer reviewed manuscripts focusing on

trials with a focus in development of immune (Checkpoints, Vaccines,

a member of the MDACC Hematology-Oncology Fellowship Steering

a PI, Co-PI or collaborator on extramural grants including Leukemia

Best of ASH-2016 & 21st Annual CME in Hematology

then did a residency in Pediatrics from Sir HN Hospital & Research

to obtain advanced training in Pediatric Hematology Oncology

Marrow Transplant at Penn State Hershey Children's Hospital in 2014.

her fellowship, the death of a teenaged patient due to a rare form of

found that a newly discovered small molecule TIC10 (now ONC201)

early success helped her obtain prestigious research grants like

then joined the Children's Hospital of Philadelphia's Cancer

to their unprecedented success, CAR-T based immunotherapies have

role, she also actively pursues translational research in further

Best of ASH-2016 & 21st Annual CME in Hematology

is a renowned Retrovirologist who has pioneered research on

the vaccines developed and tested in Dr. Franchini's laboratory is in

on scientific committees, faculties, and advisory and review

major research interests are: (1) to investigate how HTLV-1

Best of ASH-2016 & 21st Annual CME in Hematology

Professor of Internal Medicine at the University of Milan and the

and medical science research has focused on the investigation of

in the prevalence and mechanism of coagulation disorders

have been published across well-known specialized journals (IF of about

been the successful recipient of more than 40 project grants funded